alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
DEFENSE LOGISTICS AGENCY 

DLA Land and Maritime 

Contact Us

Please select a topic:

Please enter your comment or question:

If you would like us to contact you, please provide contact information (optional):

Name:

Email Address:

Organization Name:

Phone Number:

Privacy Advisory: 

Comments are solicited in order for DLA Land and Maritime to assist you with specific issues, answer your questions, and improve procedures. The comments provided 

may also be used to identify recurring problems or Frequently Asked Questions. Personally identifying information is solicited only if a response is requested. The 

information provided will be shared only with the office best suited to respond to your question or comment.

 

Or, save a copy of the form and send via email to: dibbs.bsm@dla.mil

Use the Submit button to send the form
APPENDIX I 

MATES III 

FINAL REPORT 

List of Substances and Their Associated Risk Factors
MATES III Final Report

Appendix I-2 

Appendix I 

List of Substances and their Associated Risk Factors 

Compound Class CAS 

Acute 

REL 

(μg/m3) 

Chronic 

REL 

(μg/m3) 

Unit risk 

(μg/m3)-1 

Acetaldehyde Carbonyls 75-07-0 9 2.7E-06 

Formaldehyde Carbonyls 50-00-0 94 3 6.0E-06 

Methyl Ethyl Ketone(MEK) Carbonyls 78-93-3 13000 

Arsenic Metal 7440-38-2 0.19 0.03 3.3E-03 

Cadmium Metal 7440-43-9 0.02 4.2E-03 

Copper Metal 7440-50-8 100 2.4 

Cr+6 Metal 18540-29-9 0.2 1.5E-01 

Lead Metal 7439-92-1 1.5 1.2E-05 

Manganese Metal 7439-96-5 0.2 

Nickel Metal 7440-02-0 6 0.05 2.6E-04 

Selenium Metal 7782-49-2 20 

Zinc Metal 7440-66-6 35 

Benz(a)anthracene PAH 56-55-3 1.1E-04 

Benzo(a)pyrene PAH 50-32-8 1.1E-03 

Benzo(b)fluoranthene PAH 205-99-2 1.1E-04 

Benzo(k)fluoranthene PAH 207-08-9 1.1E-04 

Chrysene PAH 218-01-9 1.1E-05 

Dibenz(ah)anthracene PAH 53-70-3 1.2E-03 

Indeno(123-cd)pyrene PAH 193-39-5 1.1E-04 

Naphthalene PAH 91-20-3 9 3.4E-05 

Benzene VOC 71-43-2 1300 60 2.9E-05 

Butadiene, 1,3- VOC 106-99-0 20 1.7E-04 

Carbon Tetrachloride VOC 56-23-5 1900 40 4.2E-05 

Chloroethene (Vinyl Chloride) VOC 75-01-4 180000 7.8E-05 

Chloroform VOC 67-66-3 5.3E-06 

Dibromoethane,1,2- (Ethylene Dibromide) VOC 106-93-4 7.1E-05 

Dichlorobenzene, p- VOC 106-46-7 800 1.1E-05 

Dichloroethane, 1,2- (Ethylene Dichloride) VOC 107-06-2 2.1E-05 

Ethylbenzene VOC 100-41-4 2000 2.5E-06 

Methyl tertiary-butyl ether (MTBE) VOC 1634-04-4 800 2.6E-07 

Methylene Chloride (Dichloromethane) VOC 75-09-2 14000 400 1.0E-06 

Perchloroethylene VOC 127-18-4 20000 5.9E-06 

Styrene VOC 100-42-5 21000 900 

Toluene VOC 108-88-3 37000 300 

Trichloroethene VOC 79-01-6 600 2.0E-06 

Xylene, o- VOC 95-47-6 22000 700 

Xylenes, (m+p)- VOC 

108-38-3/106-

42-3 22000 700 

Diesel Particulate Matter 5 3.0E-4 

Values for the above table are from the Consolidated Table of OEHHA/ARB Approved Risk 

Assessment Health Values available at http://www.arb.ca.gov/toxics/healthval/healthval.htm.
Contact Profile: Create 

Contacts can neither create nor delete a contact profile. When a contact first successfully logs in, a contact 

profile is automatically created. The contact can then edit the profile. 

Contact Profile: Edit

1. From the Home page, select the “Contact Profile” link.

2. The Contact Profile page is displayed in edit mode.

Notes:

a. Select the press release types to receive notifications.

b. If any notification types are for “Selected Materials”, make material selections.
```
[Federal Register Volume 63, Number 142 (Friday, July 24, 1998)]
[Notices]
[Page 39882]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-19798]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice 
of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel.
    Date: August 3-4, 1998.
    Time: 8:00 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver 
Spring, MD 20910.
    Contact Person: Gopal M. Bhatnagar, Phd., Scientific Review 
Administrator, Division of Scientific Review, National Institute of 
Child Health, and Human Development, National Institutes of Health, 
PHS, DHHS, 9000 Rockville Pike, 6100 Bldg., Room 5E01, Bethesda, MD 
20892, (301) 496-1485.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: July 17, 1998.
LaVerne Y. Stringfield,
Commttee Management Officer, NIH.
[FR Doc. 98-19798 Filed 7-23-98; 8:45 am]
BILLING CODE 4140-01-M
```
# EUA Fact Sheets 10-03-2023

https://www.cdc.gov/vaccines/covid-19/eua/pfizer-over-5-months.htmlhttps://www.cdc.gov/vaccines/covid-19/eua/pfizer-over-5-months.pdfhttps://www.cdc.gov/vaccines/covid-19/eua/moderna-over-5-months.htmlhttps://www.cdc.gov/vaccines/covid-19/eua/moderna-over-5-months.pdfhttps://www.cdc.gov/vaccines/covid-19/eua/novavax.htmlhttps://www.cdc.gov/vaccines/covid-19/eua/novavax.pdfhttps://www.cdc.gov/vaccines/hcp/vis/vis-statements/COVID-19.htmlhttps://www.cdc.gov/vaccines/hcp/vis/vis-statements/COVID-19.pdf
______________________________________________________________________________

Appendix 5 : Affidavit of Publication for Rules 310, 310.01 and Dust Control Permit 

Application Package

Page 199 of 720
Page 200 of 720
Page 201 of 720
Page 202 of 720
Page 203 of 720
Page 204 of 720
Page 205 of 720
Page 206 of 720
Page 207 of 720
Page 208 of 720
EXHIBIT 10.06


 


COMPENSATION AGREEMENT


 


This Compensation Agreement
is dated as of July 1, 2014 between NewLead Holdings Ltd., a Bermuda exempted company (the “Company”), and Richard
L. Thacker (the “Consultant”).


 


WHEREAS, the
Company has requested the Consultant to provide the Company with certain managing and supervising mining operations services in
connection with its business (the “Services”) and the Consultant has agreed to provide the Company with the
Services through December 31, 2014; and


 


WHEREAS, the
Company wishes to compensate the Consultant through the payment to the Consultant of 1,000,000 shares of its common stock, par
value $0.01 per share (the “Shares”), with the understanding between the Company and the Consultant that such
shares are expected to have a value of $0.25 per Share.


 


NOW THEREFORE,
in consideration of the mutual covenants hereinafter stated, it is agreed as follows:


 


1.          The Company shall issue 1,000,000
Shares to the Consultant, as consideration for the Services rendered through December 31, 2014. The Company shall register all
1,000,000 Shares on a Form S-8 under this Compensation Agreement. The registration statement shall be filed promptly following
the execution of this Compensation Agreement.


 


IN WITNESS WHEREOF,
this Compensation Agreement has been executed by the parties as of the date first above written.


 


	 	CONSULTANT	 
	 	 	 	 
	 	By:	/s/ RICHARD L. THACKER	 
	 	 	Richard L. Thacker	 
	 	 	 	 
	 	The Company: 	 
	 	 	 
	 	NEWLEAD HOLDINGS LTD.	 
	 	 	 	 
	 	By:	/s/ MICHAEL ZOLOTAS	 
	 	 	Michael Zolotas	 
	 	 	Chief Executive Officer
Privacy Reminders

13. Teleworking and PII

When you telework, do you take home Privacy Act (PA) or Personally Identifiable 

Information (PII) data? If so, the Department of Defense and DLA require you to follow 

specific procedures.

BEFORE removing documents that contain PII from the worksite, be familiar with DLA’s 

procedures for safeguarding PA and PII data while in a telework status. Review DLA

Instruction 7212, “Defense Logistics Agency Telework Program” dated December 6, 2010,

as it provides the following guidance:

1. Prior to removing any documents from the worksite, the employee will make a list 

of all the documents that will be removed and provide the list to their supervisor to 

ensure accountability of all documents.

2. All PA and PII data must be marked with the appropriate documentation and 

covered with a DLA Form 1880, DLA Privacy Act Cover Sheet.

3. All documents must be kept in an enclosed container when transporting them to 

and from alternate worksites. Open-hand carrying of documents is not permitted.

4. Documents and laptop computers may not be left unattended in a private vehicle

or other conveyance at any time.

5. Once at the telework site, the information must be maintained in a

controlled environment where no others have access, including family

members.

6. When the work has been completed, the documents must be placed in a locked 

cabinet until they are returned to the worksite.

Questions concerning protecting PII while teleworking should be referred to your local

Privacy Officer.

<Return to Reminders Table>
bicx_ex102.htm


EXHIBIT 10.2


 


AMENDMENT NO. 1 TO EXECUTIVE SERVICE AGREEMENT







This AMENDMENT NO. 1 to EXECUTIVE SERVICE AGREEMENT (“Amendment”) dated June 30, 2014 is an amendment to that certain Executive Service Agreement ("Executive Agreement") dated October 16, 2013, by and between BioCorRx, Inc., formerly known as Fresh Start Private Management, Inc, a Nevada corporation (the “Company”), and the undersigned individual, Brady Granier (the “Executive”).







WHEREAS, on October 16, 2103 the Executive and the Company entered into the Executive Agreement (the “Original Agreement”); and







WHEREAS, the Executive and the Company have agreed to enter into this Amendment to amend the Original Agreement.







NOW, THEREFORE, the Executive and the Company agree as follows:







1. Insertion of Section 5.4. The following section is inserted immediately following Section 5.3 of the Original Agreement:


 



“5.4  Notwithstanding the termination of this Agreement pursuant to Section 5.1, a notice of non-renewal pursuant to Section 6.1, or any other provision in Exhibit A, following the termination of this Agreement and until the fifteenth anniversary of the Termination Date, the Executive shall receive three percent (3%) of the Company’s gross margin of sales of then-current healthcare products, devices and/or modifications thereto thereafter.”


 


2. Affirmation of Remaining Terms and Conditions. The Company and the Executive affirm that all of the other terms and conditions of the Original Agreement shall continue in full force and effect.







[Signature Page Follows]


 




  





1











  






 


IN WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above.


 




	 	COMPANY:	 
	 	 	 
	 	BIOCORRX, INC.	 
	 	 	 	 
	
  

	
By: 

	/s/ Neil Muller	 
	 	Name: 	Neil Muller	 
	 	Title:	President	 
	 	 	 	 
	 	EXECUTIVE:	 
	 	 	 
	 	By:	/s/ Brady Granier	 
	 	Name: 	Brady Granier	 







 


 


2
| Name of Subsidiary             | State of Incorporation |
|--------------------------------|------------------------|
|                           |                   |
| Barry Scott Companies, Inc.(1) | Delaware               |
| Blast Acquisition Corp.        | Delaware               |
| Blast BSA Inc. (2)             | New York               |
| Blast DA, Inc. (2)             | Delaware               |
| Intandem Corp.                 | New York               |
| Payments Inc.                  | New York               |
| Kingstone Insurance Company    | New York               |
| CMIC Properties, Inc. (3)      | New York               |
| 15 Joys Lane, LLC (4)          | New York               |
| Comutual Services LLC (3)      | New York               |

| (1)   | A wholly-owned subsidiary of Blast Acquisition Corp. |
|-----------------|------------------------------------------------------|

| (2)   | A wholly-owned subsidiary of Barry Scott Companies, Inc. |
|-----------------|----------------------------------------------------------|

| (3)   | A wholly-owned subsidiary of Kingstone Insurance Company |
|-----------------|----------------------------------------------------------|

| (4)   | A wholly-owned subsidiary of CMIC Properties, Inc. |
|-----------------|----------------------------------------------------|
No. 11-6197.

#### Rodney Branham, Petitioner v. Michigan Department of Corrections, et al.

565 U.S. 1011, 132 S. Ct. 572,

181 L. Ed. 2d 393,

2011 U.S. LEXIS 7958.

November 7, 2011.

Motion of petitioner for leave to proceed in forma pau-peris denied, and petition for writ of cer-tiorari to the United States Court of Appeals for the Sixth Circuit dismissed. *394See Rule 39.8. As petitioner has repeatedly abused this Court’s process, the Clerk is directed not to accept any further petitions in noncriminal matters from petitioner unless the docketing fee required by Rule 38(a) is paid and petition submitted in compliance with Rule 33.1. See Martin v. District of Columbia Court of Appeals, 506 U.S. 1, 113 S. Ct. 397, 121 L. Ed. 2d 305 (1992) (per curiam).
No. 11-5184.

#### David Sanchez, Petitioner v. H. A. Ledezma, Warden; and Ponciano Torres, Petitioner v. H. A. Ledezma, Warden.

565 U.S. 946, 132 S. Ct. 401,

181 L. Ed. 2d 262,

2011 U.S. LEXIS 7404.

October 11, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.

*263Same case below, 422 Fed. Appx. 735 (first judgment); and 428 Fed. Appx. 789 (second judgment).
No. 11-5637.

#### Barry Dockery, Petitioner v. United States.

565 U.S. 917, 132 S. Ct. 335,

181 L. Ed. 2d 209,

2011 U.S. LEXIS 5893.

October 3, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.

Same case below, 423 Fed. Appx. 487.
Evaluation of 2002 Multi-pollutant Platform: Air Toxics, Ozone, and 

Particulate Matter

Sharon Phillips, Kai Wang, Carey Jang, Norm Possiel, Madeleine Strum, and Tyler Fox

Main Contact: Sharon Phillips, Air Quality Modeling Group, Office of Air Quality Planning and 

Standards, USEPA, MD: D243-01, 109 T.W. Alexander Drive, RTP, NC 27711

E-mail: phillips.sharon@epa.gov

ABSTRACT

An annual 2002 multi-pollutant model application and evaluation study was performed for the 

continental United States using a multi-pollutant version of the U.S. EPA’s Community Multiscale Air Quality (CMAQ) modeling system at grid resolutions of 36-km continental U.S. and 

12-km Eastern U.S. The CMAQ multi-pollutant v4.6.1 was developed to predict ozone, 

particulate matter, mercury, and 38 other hazardous air pollutants (HAPs) within one model 

simulation. The focus of this effort is the evaluation of model predictions of toxics species 

(including metals) and mercury deposition using 2002 measured data. Model evaluation results 

for ozone, PM2.5 component species and precursor gases, and deposition of sulfate and nitrate 

will also be presented. Based on the 36-km and 12-km 2002 simulations, sulfate predictions 

compare very well with measurements over the summer months in the eastern U.S. where sulfate 

is the dominant PM2.5 species. The model appears to simulate the total nitrate (nitrate PM and 

nitric acid, HNO3) fairly well, but the partitioning between nitrate PM and HNO3 leads to modest 

scatter in predictions of nitrate PM. Hourly and eight-hour maximum ozone model performance 

shows good agreement with ambient measurements during the ozone season (May, June, July, 

August, and September). Model performance for some non-ubiquitous HAPs shows a general 

under-prediction tendency. This paper will discuss HAP model performance in terms of: (1) 

uncertainties in monitoring methods, (2) limited measurements in time and space to characterize 

ambient concentrations, (3) commensurability issues between measurements and model 

predictions, (4) HAP monitoring issues, (3) HAP inventory issues, and/or (4) boundary

conditions, emissions, and science uncertainty issues. This paper will also examine model 

predictions to gain a better understanding of the chemical and physical interactions between

concentration and deposition of ozone, PM2.5 component species, toxic species, and precursor 

gases (including gaseous toxics) as well as their temporal and spatial relationships and the extent 

that model performance varies between the 36-km versus 12-km simulations.
*DLM 4000.25, Volume 2, November 26, 2019*

*Change 13*

**AP8.7. APPENDIX 8.7**

**REQUISITION CANCELLATION**

AP8.7-1	APPENDIX 8.7
No. 11-66.

#### Joe Alfred Izen, Jr., Petitioner v. Commission on Lawyer Discipline.

565 U.S. 881, 132 S. Ct. 248,

181 L. Ed. 2d 142,

2011 U.S. LEXIS 5584.

October 3, 2011.

Petition for writ of certiorari to the Court of Appeals of Texas, First District, denied.

Same case below, 322 S.W.3d 308.
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

1

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

RAMIRO SANDOVAL ACOSTA,

 Petitioner,

 v.

ERIC H. HOLDER Jr., Attorney General,

 Respondent.

No. 06-75798

Agency No. A091-710-582

MEMORANDUM *

On Petition for Review of an Order of the

Board of Immigration Appeals

Submitted February 11, 2010** 

San Francisco, California

Before: NOONAN, BERZON and IKUTA, Circuit Judges.

Ramiro Sandoval Acosta petitions for review of the Board of Immigration

Appeal’s (BIA) denial of his application for cancellation of removal. This Court

has jurisdiction to review questions of law. 8 U.S.C. § 1252(a)(2)(D). We review

FILED

FEB 19 2010

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2

de novo and without deference the BIA’s interpretation of the Federal First

Offender Act (FFOA), 18 U.S.C. § 3607, because the agency does not administer

the statute. De Jesus Melendez v. Gonzales, 503 F.3d 1019, 1023 (9th Cir. 2007). 

We deny the petition. 

The BIA properly concluded that Sandoval Acosta was ineligible for

cancellation of removal under 8 U.S.C. § 1229b(b)(1)(C) because he was

“convicted of . . . a violation of . . . a[ ] law . . . relating to a controlled substance,” 

8 U.S.C. § 1182(a)(2)(A), and was, therefore, statutorily barred from establishing

good moral character. Sandoval Acosta pleaded guilty to a 1999 charge under

California Health & Safety Code § 11350 for possession of cocaine and received a

deferred adjudication. The 1999 offense was not eligible for treatment as a first

offense under the Federal First Offender Act, 18 U.S.C. § 3607, such that Sandoval

Acosta could avoid deportation. See Lujan-Armendariz v. I.N.S., 222 F.3d 728,

749–50 (9th Cir. 2000). Sandoval Acosta’s 1985 “participation in California’s

pretrial diversion on a similar charge [to his 1999 controlled substances charge]

constituted his one bite at FFOA-type treatment.” De Jesus Melendez, 503 F.3d at

1025. He need not have pleaded guilty to the 1985 charge for this to be so. Id. at

1026. 
3

The disposition of the 1999 offense, therefore, falls within the Immigration

and Nationality Act’s definition of “conviction,” 8 U.S.C. § 1101(a)(48)(A), and

Sandoval Acosta was statutorily barred from establishing good moral character, see

8 U.S.C. § 1101(f)(3) (cross-referencing § 1182(a)(2)(A) as a statutory bar to a

good moral character finding). The BIA did not err by denying Sandoval Acosta’s

application for cancellation of removal.

DENIED.
I 

116TH CONGRESS 

1ST SESSION H. R. 3274 

To amend the Internal Revenue Code of 1986 to allow the energy investment 

tax credit for electrochromic glass. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 13, 2019 

Mr. HORSFORD introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL 

To amend the Internal Revenue Code of 1986 to allow the 

energy investment tax credit for electrochromic glass. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Dynamic Glass Act 

5 of 2019’’. 

6 SEC. 2. INCLUSION OF ELECTROCHROMIC GLASS AS EN7 ERGY PROPERTY FOR PURPOSES OF INVEST8 MENT TAX CREDIT. 

9 (a) IN GENERAL.—Section 48(a)(2)(A)(i) of the In10 ternal Revenue Code of 1986 is amended by striking 


kjohnson on DSK79L0C42 with BILLS
2 

•HR 3274 IH

1 ‘‘and’’ at the end of subclause (III) and by adding at the 

2 end the following new subclause: 

3 ‘‘(V) energy property described in 

4 paragraph (3)(A)(viii), and’’. 

5 (b) ELECTROCHROMIC GLASS DESCRIBED.—Section 

6 48(a)(3)(A) of such Code is amended by striking ‘‘or’’ at 

7 the end of clause (vi), by adding ‘‘or’’ at the end of clause 

8 (vii), and by adding at the end the following new clause: 

9 ‘‘(viii) glass which uses electricity to 

10 change its light transmittance properties in 

11 order to heat or cool a structure, but only 

12 with respect to property the construction 

13 of which begins before January 1, 2022.’’. 

14 (c) PHASEOUT.—Section 48(a)(6) of such Code is 

15 amended— 

16 (1) by striking ‘‘paragraph (3)(A)(i)’’ each 

17 place it appears and inserting ‘‘clause (i) or (viii) of 

18 paragraph (3)(A)’’, and 

19 (2) by inserting ‘‘AND ELECTROCHROMIC

20 GLASS’’ after ‘‘SOLAR ENERGY PROPERTY’’. 

21 (d) EFFECTIVE DATE.—The amendment made by 

22 this section shall apply to taxable years beginning after 

23 the date of the enactment of this Act. 

Æ 


kjohnson on DSK79L0C42 with BILLS
<page> EXHIBIT 32.01

CERTIFICATION OF PRESIDENT PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of Morgan Stanley Charter
WCM L.P. (the ?Partnership?) on Form 10-Q for the quarter ended
September 30, 2006 as filed with the Securities and Exchange
Commission on the date hereof (the ?Report?), I, Walter Davis,
President of Demeter Management Corporation, the general partner
of the Partnership, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that, to the best of my knowledge:
(1)	The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents,
in all material respects, the financial condition and
results of operations of the Partnership.









By:   /s/ Walter Davis

Name:		Walter Davis
Title:	President of Demeter Management Corporation,
			the general partner of the Partnership

Date:		November 14, 2006